Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression

Autores
Guilloux, Jean Philippe; Bassi, Sabrina Cecilia; Ding, Ying; Walsh, Chris; Turecki, Gustavo; Tseng, George; Cyranowski, Jill M.; Sibille, Etienne
Año de publicación
2014
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Major depressive disorder (MDD) in general, and anxious-depression in particular, are characterized by poor rates of remission with first-line treatments, contributing to the chronic illness burden suffered by many patients. Prospective research is needed to identify the biomarkers predicting nonremission prior to treatment initiation. We collected blood samples from a discovery cohort of 34 adult MDD patients with co-occurring anxiety and 33 matched, nondepressed controls at baseline and after 12 weeks (of citalopram plus psychotherapy treatment for the depressed cohort). Samples were processed on gene arrays and group differences in gene expression were investigated. Exploratory analyses suggest that at pretreatment baseline, nonremitting patients differ from controls with gene function and transcription factor analyses potentially related to elevated inflammation and immune activation. In a second phase, we applied an unbiased machine learning prediction model and corrected for model-selection bias. Results show that baseline gene expression predicted nonremission with 79.4% corrected accuracy with a 13-gene model. The same gene-only model predicted nonremission after 8 weeks of citalopram treatment with 76% corrected accuracy in an independent validation cohort of 63 MDD patients treated with citalopram at another institution. Together, these results demonstrate the potential, but also the limitations, of baseline peripheral blood-based gene expression to predict nonremission after citalopram treatment. These results not only support their use in future prediction tools but also suggest that increased accuracy may be obtained with the inclusion of additional predictors (eg, genetics and clinical scales).
Fil: Guilloux, Jean Philippe. Universite Paris Sud; Francia. University of Pittsburgh; Estados Unidos
Fil: Bassi, Sabrina Cecilia. University of Pittsburgh; Estados Unidos. Hospital Italiano. Instituto de Ciencias Básicas y Medicina Experimental; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Ding, Ying. University of Pittsburgh; Estados Unidos
Fil: Walsh, Chris. University of Pittsburgh; Estados Unidos
Fil: Turecki, Gustavo. Douglas Mental Health Institute; Canadá
Fil: Tseng, George. University of Pittsburgh; Estados Unidos
Fil: Cyranowski, Jill M.. University of Pittsburgh; Estados Unidos
Fil: Sibille, Etienne. University of Pittsburgh; Estados Unidos
Materia
Depression
Blood
Gene Expression
Biomarker
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/35959

id CONICETDig_d9fcead24473c8900a436bf140a96f46
oai_identifier_str oai:ri.conicet.gov.ar:11336/35959
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major DepressionGuilloux, Jean PhilippeBassi, Sabrina CeciliaDing, YingWalsh, ChrisTurecki, GustavoTseng, GeorgeCyranowski, Jill M.Sibille, EtienneDepressionBloodGene ExpressionBiomarkerhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Major depressive disorder (MDD) in general, and anxious-depression in particular, are characterized by poor rates of remission with first-line treatments, contributing to the chronic illness burden suffered by many patients. Prospective research is needed to identify the biomarkers predicting nonremission prior to treatment initiation. We collected blood samples from a discovery cohort of 34 adult MDD patients with co-occurring anxiety and 33 matched, nondepressed controls at baseline and after 12 weeks (of citalopram plus psychotherapy treatment for the depressed cohort). Samples were processed on gene arrays and group differences in gene expression were investigated. Exploratory analyses suggest that at pretreatment baseline, nonremitting patients differ from controls with gene function and transcription factor analyses potentially related to elevated inflammation and immune activation. In a second phase, we applied an unbiased machine learning prediction model and corrected for model-selection bias. Results show that baseline gene expression predicted nonremission with 79.4% corrected accuracy with a 13-gene model. The same gene-only model predicted nonremission after 8 weeks of citalopram treatment with 76% corrected accuracy in an independent validation cohort of 63 MDD patients treated with citalopram at another institution. Together, these results demonstrate the potential, but also the limitations, of baseline peripheral blood-based gene expression to predict nonremission after citalopram treatment. These results not only support their use in future prediction tools but also suggest that increased accuracy may be obtained with the inclusion of additional predictors (eg, genetics and clinical scales).Fil: Guilloux, Jean Philippe. Universite Paris Sud; Francia. University of Pittsburgh; Estados UnidosFil: Bassi, Sabrina Cecilia. University of Pittsburgh; Estados Unidos. Hospital Italiano. Instituto de Ciencias Básicas y Medicina Experimental; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Ding, Ying. University of Pittsburgh; Estados UnidosFil: Walsh, Chris. University of Pittsburgh; Estados UnidosFil: Turecki, Gustavo. Douglas Mental Health Institute; CanadáFil: Tseng, George. University of Pittsburgh; Estados UnidosFil: Cyranowski, Jill M.. University of Pittsburgh; Estados UnidosFil: Sibille, Etienne. University of Pittsburgh; Estados UnidosNature Publishing Group2014-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/35959Guilloux, Jean Philippe; Bassi, Sabrina Cecilia; Ding, Ying; Walsh, Chris; Turecki, Gustavo; et al.; Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression; Nature Publishing Group; Neuropsychopharmacology; 40; 3; 9-2014; 701-7100893-133XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1038/npp.2014.226info:eu-repo/semantics/altIdentifier/url/https://www.nature.com/articles/npp2014226info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:37:34Zoai:ri.conicet.gov.ar:11336/35959instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:37:34.719CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression
title Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression
spellingShingle Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression
Guilloux, Jean Philippe
Depression
Blood
Gene Expression
Biomarker
title_short Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression
title_full Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression
title_fullStr Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression
title_full_unstemmed Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression
title_sort Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression
dc.creator.none.fl_str_mv Guilloux, Jean Philippe
Bassi, Sabrina Cecilia
Ding, Ying
Walsh, Chris
Turecki, Gustavo
Tseng, George
Cyranowski, Jill M.
Sibille, Etienne
author Guilloux, Jean Philippe
author_facet Guilloux, Jean Philippe
Bassi, Sabrina Cecilia
Ding, Ying
Walsh, Chris
Turecki, Gustavo
Tseng, George
Cyranowski, Jill M.
Sibille, Etienne
author_role author
author2 Bassi, Sabrina Cecilia
Ding, Ying
Walsh, Chris
Turecki, Gustavo
Tseng, George
Cyranowski, Jill M.
Sibille, Etienne
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Depression
Blood
Gene Expression
Biomarker
topic Depression
Blood
Gene Expression
Biomarker
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Major depressive disorder (MDD) in general, and anxious-depression in particular, are characterized by poor rates of remission with first-line treatments, contributing to the chronic illness burden suffered by many patients. Prospective research is needed to identify the biomarkers predicting nonremission prior to treatment initiation. We collected blood samples from a discovery cohort of 34 adult MDD patients with co-occurring anxiety and 33 matched, nondepressed controls at baseline and after 12 weeks (of citalopram plus psychotherapy treatment for the depressed cohort). Samples were processed on gene arrays and group differences in gene expression were investigated. Exploratory analyses suggest that at pretreatment baseline, nonremitting patients differ from controls with gene function and transcription factor analyses potentially related to elevated inflammation and immune activation. In a second phase, we applied an unbiased machine learning prediction model and corrected for model-selection bias. Results show that baseline gene expression predicted nonremission with 79.4% corrected accuracy with a 13-gene model. The same gene-only model predicted nonremission after 8 weeks of citalopram treatment with 76% corrected accuracy in an independent validation cohort of 63 MDD patients treated with citalopram at another institution. Together, these results demonstrate the potential, but also the limitations, of baseline peripheral blood-based gene expression to predict nonremission after citalopram treatment. These results not only support their use in future prediction tools but also suggest that increased accuracy may be obtained with the inclusion of additional predictors (eg, genetics and clinical scales).
Fil: Guilloux, Jean Philippe. Universite Paris Sud; Francia. University of Pittsburgh; Estados Unidos
Fil: Bassi, Sabrina Cecilia. University of Pittsburgh; Estados Unidos. Hospital Italiano. Instituto de Ciencias Básicas y Medicina Experimental; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Ding, Ying. University of Pittsburgh; Estados Unidos
Fil: Walsh, Chris. University of Pittsburgh; Estados Unidos
Fil: Turecki, Gustavo. Douglas Mental Health Institute; Canadá
Fil: Tseng, George. University of Pittsburgh; Estados Unidos
Fil: Cyranowski, Jill M.. University of Pittsburgh; Estados Unidos
Fil: Sibille, Etienne. University of Pittsburgh; Estados Unidos
description Major depressive disorder (MDD) in general, and anxious-depression in particular, are characterized by poor rates of remission with first-line treatments, contributing to the chronic illness burden suffered by many patients. Prospective research is needed to identify the biomarkers predicting nonremission prior to treatment initiation. We collected blood samples from a discovery cohort of 34 adult MDD patients with co-occurring anxiety and 33 matched, nondepressed controls at baseline and after 12 weeks (of citalopram plus psychotherapy treatment for the depressed cohort). Samples were processed on gene arrays and group differences in gene expression were investigated. Exploratory analyses suggest that at pretreatment baseline, nonremitting patients differ from controls with gene function and transcription factor analyses potentially related to elevated inflammation and immune activation. In a second phase, we applied an unbiased machine learning prediction model and corrected for model-selection bias. Results show that baseline gene expression predicted nonremission with 79.4% corrected accuracy with a 13-gene model. The same gene-only model predicted nonremission after 8 weeks of citalopram treatment with 76% corrected accuracy in an independent validation cohort of 63 MDD patients treated with citalopram at another institution. Together, these results demonstrate the potential, but also the limitations, of baseline peripheral blood-based gene expression to predict nonremission after citalopram treatment. These results not only support their use in future prediction tools but also suggest that increased accuracy may be obtained with the inclusion of additional predictors (eg, genetics and clinical scales).
publishDate 2014
dc.date.none.fl_str_mv 2014-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/35959
Guilloux, Jean Philippe; Bassi, Sabrina Cecilia; Ding, Ying; Walsh, Chris; Turecki, Gustavo; et al.; Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression; Nature Publishing Group; Neuropsychopharmacology; 40; 3; 9-2014; 701-710
0893-133X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/35959
identifier_str_mv Guilloux, Jean Philippe; Bassi, Sabrina Cecilia; Ding, Ying; Walsh, Chris; Turecki, Gustavo; et al.; Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression; Nature Publishing Group; Neuropsychopharmacology; 40; 3; 9-2014; 701-710
0893-133X
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1038/npp.2014.226
info:eu-repo/semantics/altIdentifier/url/https://www.nature.com/articles/npp2014226
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Nature Publishing Group
publisher.none.fl_str_mv Nature Publishing Group
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613184395149312
score 13.070432